MedTrace Logo

Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)

NCT02059681 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-03-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether endocavitary intramyocardial injection of autologous bone-marrow-derived CD133+ cells is safe on the basis of number of adverse events, with follow-up assessments extending up to 1 year after enrolment.

Conditions

  • Chronic Myocardial Ischemia

Interventions

OTHER

Autologous bone marrow derived-CD133+ cells

Cell therapy

Sponsors & Collaborators

  • A.O.U. Città della Salute e della Scienza

    collaborator OTHER

  • Azienda Ospedaliera San Gerardo di Monza

    collaborator OTHER

  • Centro Cardiologico Monzino

    lead OTHER

Principal Investigators

  • Giulio Pompilio, MD PhD · Centro Cardiologico Monzino, IRCCS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2022-02-28
Completion
2022-02-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02059681 on ClinicalTrials.gov